Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Agustin A. Garcia, Anne Yessaian, Huyen Pham, Grace Facio, Laila Muderspach & Lynda Roman. (2012) Phase II Study of Gemcitabine and Docetaxel in Recurrent Platinum Resistant Ovarian Cancer. Cancer Investigation 30:4, pages 295-299.
Read now
Read now
Articles from other publishers (9)
Katsunori Matsushita, Takumi Okuda, Shohei Mori, Masamitsu Konno, Hidetoshi EguchiAyumu Asai, Jun Koseki, Yoshifumi IwagamiDaisaku Yamada, Hirofumi AkitaTadafumi AsaokaTakehiro NodaKoichi Kawamoto, Kunihito GotohShogo KobayashiYuuya Kasahara, Kunihiko Morihiro, Taroh Satoh, Yuichiro DokiMasaki Mori, Hideshi Ishii & Satoshi Obika. (2019) A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. ChemMedChem 14:15, pages 1384-1391.
Crossref
Crossref
Martyna Krzykawska-Serda, Jason Chak-Shing Ho, Matthew J. Ware, Justin J. Law, Jared M. Newton, Lam Nguyen, Mahdi Agha, Steven A. Curley & Stuart J. Corr. (2018) Ultrasound Doppler as an Imaging Modality for Selection of Murine 4T1 Breast Tumors for Combination Radiofrequency Hyperthermia and Chemotherapy. Translational Oncology 11:4, pages 864-872.
Crossref
Crossref
Angela Rizzo, Sara Iachettini, Pasquale Zizza, Chiara Cingolani, Manuela Porru, Simona Artuso, Malcolm Stevens, Marc Hummersone, Annamaria Biroccio, Erica Salvati & Carlo Leonetti. (2014) Identification of novel RHPS4-derivative ligands with improved toxicological profiles and telomere-targeting activities. Journal of Experimental & Clinical Cancer Research 33:1.
Crossref
Crossref
Rui Zhang, Jiyuan Yang, Monika Sima, Yan Zhou & Jindřich Kopeček. (2014)
Sequential combination therapy of ovarian cancer with degradable
N
-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates
. Proceedings of the National Academy of Sciences 111:33, pages 12181-12186.
Crossref
Crossref
Nate Larson, Jiyuan Yang, Abhijit Ray, Darwin L. Cheney, Hamidreza Ghandehari & Jindřich Kopeček. (2013) Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment. International Journal of Pharmaceutics 454:1, pages 435-443.
Crossref
Crossref
V. Roy, B.R. LaPlant, G.G. Gross, C.L. Bane & F.M. Palmieri. (2009) Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Annals of Oncology 20:3, pages 449-453.
Crossref
Crossref
Carlo Leonetti, Marco Scarsella, Giuseppe Riggio, Angela Rizzo, Erica Salvati, Maurizio D'Incalci, Lidia Staszewsky, Roberta Frapolli, Malcolm F. Stevens, Antonella Stoppacciaro, Marcella Mottolese, Barbara Antoniani, Eric Gilson, Gabriella Zupi & Annamaria Biroccio. (2008) G-Quadruplex Ligand RHPS4 Potentiates the Antitumor Activity of Camptothecins in Preclinical Models of Solid Tumors. Clinical Cancer Research 14:22, pages 7284-7291.
Crossref
Crossref
Ezogelin Oflazoglu, Kim M. Kissler, Eric L. Sievers, Iqbal S. Grewal & Hans-Peter Gerber. (2008) Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. British Journal of Haematology 142:1, pages 69-73.
Crossref
Crossref
Dmytro M. Havaleshko, HyungJun Cho, Mark Conaway, Charles R. Owens, Garret Hampton, Jae K. Lee & Dan Theodorescu. (2007) Prediction of drug combination chemosensitivity in human bladder cancer. Molecular Cancer Therapeutics 6:2, pages 578-586.
Crossref
Crossref